Answers are grounded in this paper and cite their sources.
Demonstrates high sensitivity and specificity in lymph node metastasis detection across various cancer types, highlighting potential for clinical integration.
Lymph node metastasis assessment is critical for cancer staging, yet the process is labor-intensive and prone to variability, particularly when evaluating micro-metastases or isolated tumor cells that can directly alter treatment decisions. We present MetAssist 2.0, a modular AI system that combines a pathology foundation model with transformer-based segmentation to automate metastasis detection across cancer types. Trained on colorectal and upper gastrointestinal cancers, it was validated on 8,144 slides spanning seven cancer types and 14 multi-institutional cohorts. MetAssist 2.0 achieved at least 90% sensitivity in 13 cohorts and 91% specificity in 11, including challenging subtypes such as mucinous adenocarcinoma and tumor deposits. With only 10 annotated slides, the system adapted to unseen cancer types via few-shot fine-tuning. As a triage tool for colorectal cancer, it could reduce pathologist workload by up to 72% with a 98% sensitivity and revealed metastases missed in routine reporting. These results demonstrate broad generalizability and near clinical-grade performance, positioning MetAssist 2.0 for integration into the pathology workflows.
No takes yet. Share an insight, caveat, or question.
García-Baroja et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: